ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells | Citedby Results | Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells

Mol Cancer Ther (2010) 9 (6): 1503–1514.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer

Ziqi Li
Erika Belitzky
Ondrej Blaha
Alessandra Cavaliere
Samantha R. Katz
Mariam Aboian
Lindy Melegari
Khashayar Rajabimoghadam
Stephen Kurpiewski
Xiaohua Zhu
Bernadette Marquez-Nostra

Cancers (2023) 15 (5): 1589.

Clinical importance of her-3 in breast cancer

Libor Staněk
Petra Tesařová
Robert Gurlich
Zdeněk Musil
František Mateička

Onkologie (2020) 14 (1): 32.

UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer

Rabia A. Gilani
Sameer Phadke
Li Wei Bao
Eric J. Lachacz
Michele L. Dziubinski
Kristoffer R. Brandvold
Michael E. Steffey
Frank E. Kwarcinski
Carrie R. Graveel
Kelley M. Kidwell
Sofia D. Merajver
Matthew B. Soellner

Clinical Cancer Research (2016) 22 (20): 5087.

Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case

Katia Sotelo Monge
Alberto Gálvez-Ruiz
Alberto Alvárez-Carrón
César Quijada
Anna Matheu

Saudi Journal of Ophthalmology (2015) 29 (3): 227.

An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade

LONG LI
XIAOJUN LI
XIAOBING HAN
TING YANG
JING FU
YUNFENG ZHANG
WENLI GOU

Oncology Reports (2014) 32 (3): 943.

Synthesis and Preliminary Cytotoxicity Evaluation of New Diarylamides and Diarylureas Possessing 2,3-Dihydropyrrolo[3,2-b]quinoline Scaffold

Hyun-Jin Kim
Mohammed I. El-Gamal
Yong Sup Lee
Chang-Hyun Oh

Bulletin of the Korean Chemical Society (2013) 34 (8): 2480.

Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells

Jyoti Nautiyal
Shailender S Kanwar
Yingjie Yu
Adhip P N Majumdar

Journal of Molecular Signaling (2011) 6: 7.

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Siyuan Zhang
Wen-Chien Huang
Ping Li
Hua Guo
Say-Bee Poh
Samuel W Brady
Yan Xiong
Ling-Ming Tseng
Shau-Hsuan Li
Zhaoxi Ding
Aysegul A Sahin
Francisco J Esteva
Gabriel N Hortobagyi
Dihua Yu

Nature Medicine (2011) 17 (4): 461.

Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives

Hassan M. Shallal
Wade A. Russu

European Journal of Medicinal Chemistry (2011) 46 (6): 2043.

Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB

Xian-Hua Fu
Jun Li
Jian-Jin Huang
Shu Zheng
Su-Zhan Zhang

Cancer Chemotherapy and Pharmacology (2011) 68 (6): 1373.

Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent Inhibitor of Colon Cancer Stem-Like Cells

Shailender Singh Kanwar
Yingjie Yu
Jyoti Nautiyal
Bhaumik B. Patel
Subhash Padhye
Fazlul H. Sarkar
Adhip P. N. Majumdar

Pharmaceutical Research (2011) 28 (4): 827.

Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells

Molecular Cancer Therapeutics (2010) 9 (9): 2637.